Since the discovery of vascular endothelial growth factor (VEGF), therapeutic angiogenesis, stem-cell and progenitor-cell therapy have attracted interest as an innovative approaches to manage end-stage ischemic coronary and peripheral artery disease [1], [2]. The gene discussed is VEGFA; the disease is peripheral arterial disease.